Cargando…
A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery
Introduction Primary hyperparathyroidism (PHPT) is a disorder in which one or more parathyroid glands overproduce parathyroid hormone, leading to hypercalcemia. It may present with symptoms like constipation, abdominal pain, psychiatric complaints as well as signs of nephrolithiasis, and osteoporosi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949684/ https://www.ncbi.nlm.nih.gov/pubmed/36843806 http://dx.doi.org/10.7759/cureus.34157 |
_version_ | 1784892999083229184 |
---|---|
author | Behnke, Andrew J Tershak, Daniel R Abel, William F Bankole, Adegbenga A |
author_facet | Behnke, Andrew J Tershak, Daniel R Abel, William F Bankole, Adegbenga A |
author_sort | Behnke, Andrew J |
collection | PubMed |
description | Introduction Primary hyperparathyroidism (PHPT) is a disorder in which one or more parathyroid glands overproduce parathyroid hormone, leading to hypercalcemia. It may present with symptoms like constipation, abdominal pain, psychiatric complaints as well as signs of nephrolithiasis, and osteoporosis that may need surgical treatment. PHPT is often underdiagnosed and undertreated. Our study aimed to review hypercalcemia in a single center to evaluate for undiagnosed PHPT. Methods A group of 546 patients from Southwest Virginia was selected using the EMR Epic (Epic Systems, Verona, USA)( )who had a diagnosis of hypercalcemia in the previous six months. Charts were manually reviewed, and patients were excluded based on the lack of hypercalcemia as well as previous testing of parathyroid hormone (PTH) levels. One hundred and fifty patients were excluded because of a lack of documented hypercalcemia. Letters were sent to the patients advising the patients to discuss whether a PTH would be indicated with their primary care provider (PCP). These patients’ charts were re-examined six months later and a determination of whether a PTH level was performed as well as any referrals explicitly for hypercalcemia or PHPT was done. Results A total of 20 (5.1%) patients had a new PTH test during the time assessed. Of these patients, five received referrals to surgical treatment and six received referrals to endocrinology for treatment (no patients received referrals to both). Of those who obtained a PTH level, 50% of them had significantly elevated PTH levels consistent with the diagnosis of primary hyperparathyroidism. An additional 45% had levels of parathyroid hormone that were in the normal range but or most likely inappropriately normal for the concurrent level of calcium. Only one patient (5%) had a suppressed PTH level. Conclusion The impact of an intervention on clinician evaluation and treatment of patients with hypercalcemia has been previously tested and shown to be beneficial. In this study, the method of directly sending a letter to patients yielded clinically significant results, with 20 patients out of 396 (5.1%) having a PTH level tested. A majority had an overt or suspected parathyroid disease, and out of them, 11 underwent referral for treatment. |
format | Online Article Text |
id | pubmed-9949684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-99496842023-02-24 A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery Behnke, Andrew J Tershak, Daniel R Abel, William F Bankole, Adegbenga A Cureus Endocrinology/Diabetes/Metabolism Introduction Primary hyperparathyroidism (PHPT) is a disorder in which one or more parathyroid glands overproduce parathyroid hormone, leading to hypercalcemia. It may present with symptoms like constipation, abdominal pain, psychiatric complaints as well as signs of nephrolithiasis, and osteoporosis that may need surgical treatment. PHPT is often underdiagnosed and undertreated. Our study aimed to review hypercalcemia in a single center to evaluate for undiagnosed PHPT. Methods A group of 546 patients from Southwest Virginia was selected using the EMR Epic (Epic Systems, Verona, USA)( )who had a diagnosis of hypercalcemia in the previous six months. Charts were manually reviewed, and patients were excluded based on the lack of hypercalcemia as well as previous testing of parathyroid hormone (PTH) levels. One hundred and fifty patients were excluded because of a lack of documented hypercalcemia. Letters were sent to the patients advising the patients to discuss whether a PTH would be indicated with their primary care provider (PCP). These patients’ charts were re-examined six months later and a determination of whether a PTH level was performed as well as any referrals explicitly for hypercalcemia or PHPT was done. Results A total of 20 (5.1%) patients had a new PTH test during the time assessed. Of these patients, five received referrals to surgical treatment and six received referrals to endocrinology for treatment (no patients received referrals to both). Of those who obtained a PTH level, 50% of them had significantly elevated PTH levels consistent with the diagnosis of primary hyperparathyroidism. An additional 45% had levels of parathyroid hormone that were in the normal range but or most likely inappropriately normal for the concurrent level of calcium. Only one patient (5%) had a suppressed PTH level. Conclusion The impact of an intervention on clinician evaluation and treatment of patients with hypercalcemia has been previously tested and shown to be beneficial. In this study, the method of directly sending a letter to patients yielded clinically significant results, with 20 patients out of 396 (5.1%) having a PTH level tested. A majority had an overt or suspected parathyroid disease, and out of them, 11 underwent referral for treatment. Cureus 2023-01-24 /pmc/articles/PMC9949684/ /pubmed/36843806 http://dx.doi.org/10.7759/cureus.34157 Text en Copyright © 2023, Behnke et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Endocrinology/Diabetes/Metabolism Behnke, Andrew J Tershak, Daniel R Abel, William F Bankole, Adegbenga A A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery |
title | A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery |
title_full | A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery |
title_fullStr | A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery |
title_full_unstemmed | A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery |
title_short | A Therapeutic Approach to Primary Hyperparathyroidism: A Collaborative Evaluation Between Endocrinology and Surgery |
title_sort | therapeutic approach to primary hyperparathyroidism: a collaborative evaluation between endocrinology and surgery |
topic | Endocrinology/Diabetes/Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949684/ https://www.ncbi.nlm.nih.gov/pubmed/36843806 http://dx.doi.org/10.7759/cureus.34157 |
work_keys_str_mv | AT behnkeandrewj atherapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT tershakdanielr atherapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT abelwilliamf atherapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT bankoleadegbengaa atherapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT behnkeandrewj therapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT tershakdanielr therapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT abelwilliamf therapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery AT bankoleadegbengaa therapeuticapproachtoprimaryhyperparathyroidismacollaborativeevaluationbetweenendocrinologyandsurgery |